EXELIXIS Aktie

 

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28....

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A webcast replay of the conference call will also be archived on www.exelixis.com for one year. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of ca...

Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials....

Top-ranked stocks Urban Outfitters (URBN), Fox (FOX), Electronic Arts (EA), Uber Technologies (UBER) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service....

EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism....

EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty....

EXEL, LYFT, and KGC see broker upgrades and strong 2025 earnings growth forecasts amid volatile market conditions....

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes....

SFM, RGLD, TRI, WWD and EXEL are non-tech Nasdaq standouts with strong ranks, rising estimates and double-digit gains in 2025....

Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road....

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues....

FLEX, CVS, URBN and EXEL stand out as GARP picks with strong growth outlooks and discounted PEG ratios....

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

Palomar Holdings, Exelixis and Olo stocks all boast top Zacks Ranks, reasonable valuations and strong price momentum...